Publicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (7)

2022

  1. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  2. HER3 in cancer: from the bench to the bedside

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  3. Novel adcs and strategies to overcome resistance to anti-her2 adcs

    Cancers, Vol. 14, Núm. 1

2021

  1. Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  2. Generation of antibody‐drug conjugate resistant models

    Cancers, Vol. 13, Núm. 18

2020

  1. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms

    Cancer Letters, Vol. 470, pp. 161-169

  2. HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies

    EMBO Molecular Medicine, Vol. 12, Núm. 5